CFLAR and prostate cancer: Inhibition of CXCL8 signaling or down-regulation of c-FLIP sensitized prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- and chemotherapy (oxaliplatin)-induced apoptosis in both androgen-dependent (LNCaP) and androgen-independent (PC3) cell lines.